Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

OBJECTIVES: In the phase II FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses (FORWARD) study, sprifermin demonstrated cartilage modification in the total femorotibial joint and in both femorotibial compartments by MRI in patients with knee osteoarthritis. Here, we evaluat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Rheum Dis
Hlavní autoři: Eckstein, Felix, Kraines, Jeffrey L, Aydemir, Aida, Wirth, Wolfgang, Maschek, Susanne, Hochberg, Marc C
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Osteoarthritis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147175/
https://ncbi.nlm.nih.gov/pubmed/32098758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216453
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky